Login Register Cart 0
Generic placeholder image

Current Computer-Aided Drug Design

Editor-in-Chief

ISSN (Print): 1573-4099
ISSN (Online): 1875-6697

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking and Molecular Dynamics Simulation of New Potential JAK3 Inhibitors

Author(s): Qidi Zhong, Jiarui Qin, Kaihui Zhao, Lihong Guo and Dongmei Li*

Volume 20, Issue 6, 2024

Published on: 30 August, 2023

Page: [764 - 772] Pages: 9

DOI: 10.2174/1573409919666230525154120

Price: $65

Abstract

Introduction: JAK3 kinase inhibitor has become an effective means to treat tumors and autoimmune diseases.

Methods: In this study, molecular docking and molecular dynamics simulation were used to study the theoretical interaction mechanism between 1-phenylimidazolidine-2-one molecules and JAK3 protein.

Results: The results of molecular docking showed that the six 1-phenylimidazolidine-2-one derivatives obtained by virtual screening were bound to the ATP pocket of JAK3 kinase, which were competitive inhibitors of ATP, and were mainly bound to the pocket through hydrogen bonding and hydrophobic interaction. Further, MM/GBSA based on molecular dynamics simulation sampling was used to calculate the binding energy between six molecules and the JAK3 kinase protein. Subsequently, the binding energy was decomposed into the contribution of each amino acid residue, of which Leu905, Lys855, Asp967, Leu956, Tyr904, and Val836 were the main energycontributing residues. Among them, the molecule numbered LCM01415405 can interact with the specific amino acid Arg911 of JAK3 kinase, suggesting that the molecule may be a selective JAK3 kinase inhibitor. The root-mean-square fluctuation (RMSF) of JAK3 kinase pocket residues during molecular dynamics simulation showed that the combination of six new potential small molecule inhibitors with JAK3 kinase could reduce the flexibility of JAK3 kinase pocket residues.

Conclusion: These findings reveal the mechanism of 1-phenylimidazolidine-2-one derivatives on JAK3 protein and provide a relatively solid theoretical basis for the development and structural optimization of JAK3 protein inhibitors.

« Previous Next »
Graphical Abstract

[1]
Huang HZ, Zhang JX, Liu J, Xu YG, Sun LP. Research progress of Janus Kinases and their inhibitors. Prog Pharm Sci 2019; 43(1): 42-50.https://pps.cpu.edu.cn/en/article/id/f41a1521-9b2a-4aa8-a976-44234ce56f2a
[2]
Zhao JZ, Jiang XX, Li HW, et al. Carcinog. Teratogenesis. Mutagen 2020; 32: 402.
[3]
Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36(4): 503-14.
[http://dx.doi.org/10.1016/j.immuni.2012.03.013] [PMID: 22520844]
[4]
Levy DE, Darnell JE Jr. STATs: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3(9): 651-62.
[http://dx.doi.org/10.1038/nrm909] [PMID: 12209125]
[5]
Zhiqiang S, Rui W, Jiarui Q, Kaihui A, Qidi Z, Hao Z. Discovery of novel potential JAK3 small molecule inhibitors based on virtual screening strategy. Chemistry 2023; 86(1): 5.
[6]
Sabe VT, Ntombela T, Jhamba LA, et al. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem 2021; 224: 113705.
[http://dx.doi.org/10.1016/j.ejmech.2021.113705] [PMID: 34303871]
[7]
Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016; 310(3): G155-62.
[http://dx.doi.org/10.1152/ajpgi.00311.2015] [PMID: 26608188]
[8]
Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004; 1(4): 337-41.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[9]
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66(1): 311-28.
[http://dx.doi.org/10.1146/annurev-med-051113-024537]
[10]
Salomon-Ferrer R, Case DA, Walker RC. An overview of the Amber biomolecular simulation package. Wiley Interdiscip Rev Comput Mol Sci 2013; 3(2): 198-210.
[http://dx.doi.org/10.1002/wcms.1121]
[11]
Frisch MJ, Trucks GW, Schlegel J, et al. Gaussian 09, Revision C01 Inc. Wallingford CT 2010.
[12]
Wang W, Lim WA, Jakalian A, et al. An analysis of the interactions between the Sem-5 SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis. J Am Chem Soc 2001; 123(17): 3986-94.
[http://dx.doi.org/10.1021/ja003164o] [PMID: 11457149]
[13]
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case D. Development and testing of a general amber force field. J Comput Chem 2004; 25(9): 1157-74.
[14]
Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 2015; 11(8): 3696-713.
[http://dx.doi.org/10.1021/acs.jctc.5b00255] [PMID: 26574453]
[15]
Sagui C, Darden TA. Molecular dynamics simulations of biomolecules: Long-range electrostatic effects. Annu Rev Biophys Biomol Struct 1999; 28(1): 155-79.
[http://dx.doi.org/10.1146/annurev.biophys.28.1.155] [PMID: 10410799]
[16]
Kräutler V, Van GWF. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J Comput Chem 2015; 22(5): 501-8.
[http://dx.doi.org/10.1002/1096-987X(20010415)22:5<501:AID-JCC1021>3.0.CO;2-V]
[17]
Larini L, Mannella R, Leporini D. Langevin stabilization of molecular-dynamics simulations of polymers by means of quasisymplectic algorithms. J Chem Phys 2007; 126(10): 104101.
[http://dx.doi.org/10.1063/1.2464095] [PMID: 17362055]
[18]
Roe DR, Cheatham TE III. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 2013; 9(7): 3084-95.
[http://dx.doi.org/10.1021/ct400341p] [PMID: 26583988]
[19]
Chen Y, Zheng Y, Fong P, Mao S, Wang Q. The application of the MM/GBSA method in the binding pose prediction of FGFR inhibitors. Phys Chem Chem Phys 2020; 22(17): 9656-63.
[http://dx.doi.org/10.1039/D0CP00831A] [PMID: 32328599]
[20]
Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 2011; 51(1): 69-82.
[http://dx.doi.org/10.1021/ci100275a] [PMID: 21117705]
[21]
Davis AM, Riley RJ. Predictive ADMET studies, the challenges and the opportunities. Curr Opin Chem Biol 2004; 8(4): 378-86.
[http://dx.doi.org/10.1016/j.cbpa.2004.06.005] [PMID: 15288247]
[22]
Wang E, Sun H, Wang J, et al. End-Point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem Rev 2019; 119(16): 9478-508.
[http://dx.doi.org/10.1021/acs.chemrev.9b00055] [PMID: 31244000]
[23]
Sun H, Li Y, Tian S, Xu L, Hou T. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys 2014; 16(31): 16719-29.
[http://dx.doi.org/10.1039/C4CP01388C] [PMID: 24999761]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy